Microbio Co., Ltd.
TTPEX:412814.80
TWD
-0.30
(-1.99%)
ISIN
TW0004128004
Return %
Stock
S&P 500
1Y
-33.93
14.20
3Y
-68.86
81.12
5Y
-69.50
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Ming Lian Kuo
- Full Time Employees
- 577
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- No. 3, Park St. Taipei TP Taiwan 115
- IPO Date
- Feb 10, 2003
- Website
- microbio.com.tw
- Similar Companies
- Business
- Microbio Co., Ltd. engages in the research, development, manufacture, and sale of biotech drugs, healthcare products, and dietary supplements primarily in Taiwan. The company’s main product offerings include botanical drugs such as MS-20, health foods, herbal products under the LeeHerb series, top-quality enzyme drinks, functional foods, disease prevention and nutrient supplements, as well as organic agricultural products including vegetables, fruits, nuts, pastry, and seasonings. The company also manufactures new medicines targeting diseases such as cancer, hepatitis, allergy, and rheumatoid arthritis. Microbio supplies raw materials to pharmaceutical companies and is involved in fermentation technology and microbial pharmaceutical platform development. The company was founded in May 2000 and is headquartered in Taipei, Taiwan. In recent years, Microbio has pursued active innovation with a focus on high-end new medicines and medical care products. Its strategic developments include obtaining new drug certificates for products like Chemo Young and Herbiron, which are approved by the Taiwanese Ministry of Health and Welfare. Microbio continues to emphasize its R&D capabilities with a first-class team, leading to breakthroughs in biotechnology. In terms of notable recent changes, the company has expanded its new drug research and development segment, achieving increased revenue in this area. It also withdrew its 510(k) application for the MB107 cream medical device due to changes in FDA review requirements and is engaging in various partnerships and distribution agreements to broaden its market reach. Microbio operates predominantly within the biotechnology, pharmaceutical, health food, and functional food industries and targets healthcare providers, pharmaceutical companies, and health-conscious consumers, both domestically in Taiwan and increasingly through strategic overseas distribution. The company maintains a biotechnology enterprise group structure that includes organic agriculture and venture capital for biotechnology startups, reinforcing its positioning in biotech innovation and health product markets. Overall, Microbio Co., Ltd. combines its strong R&D foundation in biotech drug development with commercial operations in health supplements and clinical botanical drugs, sustaining growth through new pharmaceutical approvals and expanding product lines in health and medical care sectors. It remains committed to innovation and corporate social responsibility while maintaining its headquarters in Taipei, Taiwan. This description encompasses Microbio’s core business segments, product portfolio, geographic orientation, founding background, and recent strategic and operational developments.